| pubmed-article:2661242 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2661242 | lifeskim:mentions | umls-concept:C0027396 | lld:lifeskim |
| pubmed-article:2661242 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:2661242 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:2661242 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:2661242 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2661242 | pubmed:dateCreated | 1989-8-1 | lld:pubmed |
| pubmed-article:2661242 | pubmed:abstractText | The pharmacokinetics and clinical efficacy of a once-daily sustained-release formulation of naproxen (sodium salt) have been compared with those of conventional-release agents. In a single dose pharmacokinetic study, the rate of absorption of the sustained-release preparation was less than that of a conventional-release preparation but the extent of absorption was the same. As is the case with conventional-release naproxen, food decreased the rate but not the extent of absorption of the sustained-release formulation. On multiple dose administration for 7 days, the AUC and average concentrations of the sustained release preparation (1 g daily) were the same as those for conventional release preparations of naproxen sodium (250 mg four times daily) and naproxen free acid (500 mg daily). The conventional-release sodium salt was absorbed more quickly with no differences in bioavailability. A double-blind clinical comparison in patients with osteoarthritis showed the sustained-release preparation (1 g daily) to be equivalent in efficacy to conventional naproxen capsules (500 mg twice daily) but to have a significantly lower incidence of gastrointestinal side-effects. The results suggest that sustained-release naproxen sodium has potential for use as a once-daily treatment for inflammatory disease. | lld:pubmed |
| pubmed-article:2661242 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2661242 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2661242 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2661242 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2661242 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2661242 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2661242 | pubmed:issn | 0031-6970 | lld:pubmed |
| pubmed-article:2661242 | pubmed:author | pubmed-author:KellyJ GJG | lld:pubmed |
| pubmed-article:2661242 | pubmed:author | pubmed-author:DevaneJ GJG | lld:pubmed |
| pubmed-article:2661242 | pubmed:author | pubmed-author:MulliganSS | lld:pubmed |
| pubmed-article:2661242 | pubmed:author | pubmed-author:KinneyC DCD | lld:pubmed |
| pubmed-article:2661242 | pubmed:author | pubmed-author:ColganB VBV | lld:pubmed |
| pubmed-article:2661242 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2661242 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:2661242 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2661242 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2661242 | pubmed:pagination | 383-8 | lld:pubmed |
| pubmed-article:2661242 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:meshHeading | pubmed-meshheading:2661242-... | lld:pubmed |
| pubmed-article:2661242 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2661242 | pubmed:articleTitle | Pharmacokinetic properties and clinical efficacy of once-daily sustained-release naproxen. | lld:pubmed |
| pubmed-article:2661242 | pubmed:affiliation | Institute of Biopharmaceutics, Athlone, Ireland. | lld:pubmed |
| pubmed-article:2661242 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2661242 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2661242 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2661242 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
